Candel's Phase I Trial Data For CAN-2409 In High-grade Glioma Published In Neuro-Oncology

(RTTNews) - Candel Therapeutics, Inc. (CADL), Tuesday, announced the publication of Phase 1b clinical trial results for CAN-2409 in newly diagnosed high-grade glioma in the journal Neuro-Oncology.

The phase 1b clinical trial evaluated the safety and tolerability of the combination of CAN-2409 and Nivolumab plus standard of care in newly diagnosed high-grade glioma patients.

The study demonstrated encouraging survival benefits and immune activation. The trial enrolled 41 patients, with a subset showing notable improvements.

Patients with MGMT-methylated tumors who underwent total tumor resection had a median overall survival of 30.6 months. CAN-2409 treatment induced systemic immune activation, enhancing T-cell diversity and reducing immunosuppressive cells.

Although CAN-2409 is not currently being developed for high-grade glioma due to portfolio prioritization, these findings support CAN-2409's potential as a pan-solid tumor therapy, noted the company.

CAN-2409 is currently in late-stage trials for prostate cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer.

CADL is currently trading at $5.62 down $0.03 or 0.53 percent on the Nasdaq.